Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
Completed · Phase 2
Conditions studied: Kidney Transplantation
In brief
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months. Patients will be assigned to one of three treatment groups after receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be a standard-of-care control arm. Patients will continue to take the assigned study medication for 12 months as well as other standard transplant medications such as prednisone.
Key facts
- Study ID
- NCT00483756
- Run by
- Pfizer
- People needed
- 338
- Starts
- 2007-08-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2013-03-14
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
You may not qualify if…
- Recipient of any non-kidney transplant
Where it is running
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — Palo Alto, California, United States
- Pfizer Investigational Site — San Diego, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — San Francisco, California, United States
- Pfizer Investigational Site — Stanford, California, United States
- Pfizer Investigational Site — Aurora, Colorado, United States
- Pfizer Investigational Site — New Haven, Connecticut, United States
- Pfizer Investigational Site — New Haven, Connecticut, United States
- Pfizer Investigational Site — Gainesville, Florida, United States
- Pfizer Investigational Site — Gainsville, Florida, United States
- Pfizer Investigational Site — Tampa, Florida, United States
- Pfizer Investigational Site — Chicago, Illinois, United States
- Pfizer Investigational Site — Chicago, Illinois, United States
- Pfizer Investigational Site — Baltimore, Maryland, United States
- Pfizer Investigational Site — Boston, Massachusetts, United States
- Pfizer Investigational Site — Springfield, Massachusetts, United States
- Pfizer Investigational Site — Springfield, Massachusetts, United States
- Pfizer Investigational Site — Ann Arbor, Michigan, United States
- Pfizer Investigational Site — Detroit, Michigan, United States
- Pfizer Investigational Site — Rochester, Minnesota, United States
- Pfizer Investigational Site — St Louis, Missouri, United States
- Pfizer Investigational Site — Livingston, New Jersey, United States
- Pfizer Investigational Site — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.